Trials / Terminated
TerminatedNCT03144661
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.
Conditions
- Hepatocellular Carcinoma (HCC)
- Cholangiocarcinoma
- Esophageal Cancer
- Nasopharyngeal Cancer
- Ovarian Cancer
- Solid Tumors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB062079 | In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts. |
Timeline
- Start date
- 2017-05-25
- Primary completion
- 2020-06-10
- Completion
- 2020-06-10
- First posted
- 2017-05-09
- Last updated
- 2025-10-21
Locations
6 sites across 2 countries: United States, Belgium
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03144661. Inclusion in this directory is not an endorsement.